A groundbreaking study published in the Proceedings of the National Academy of Sciences has unveiled an influential axis in the pathophysiology of colitis-associated cancer (CAC): the interaction between FAM64A, a protein previously uncharted in inflammation and oncogenesis, and STAT3, a transcription factor critical for cell growth and immune response. The discovery not only broadens our scientific understanding but also has potential implications for treatment strategies for CAC and other inflammation-associated diseases.

The Interdependency of FAM64A and STAT3

The research, led by Xu Zhi-Sheng and collaborators, meticulously explored the interplay between FAM64A and STAT3, pushing the boundaries of what we know about cellular functions in immunity and cancer progression. Transcription factors like STAT3 are essential for the expression of genes that regulate cell growth and differentiation. However, unregulated activity of STAT3 can lead to a plethora of serious diseases, including inflammatory ailments and various types of cancer.

This study’s pivotal finding was that the protein FAM64A essentially acts as a regulation node for STAT3. Overexpression of FAM64A potentiates the activation of STAT3 in response to IL-6, a cytokine often involved in inflammation, and further enhances the expression of genes downstream. Conversely, deficiency of FAM64A diminishes STAT3 activity. Specifically, FAM64A facilitates STAT3’s interaction with the gene promoters it regulates, revealing a direct molecular mechanism through which FAM64A affects STAT3 function.

Implications on Th17 and CAC

Central to this study is Th17, a subset of T cells that play a critical role in the immune system, implicated in autoimmune diseases. The team discovered an intriguing selective effect on Th17 cell differentiation; FAM64A deficiency resulted in impaired differentiation of Th17 without affecting other cells like Th1 or induced regulatory T (iTreg). This finding points to a targeted regulatory process in the immune system that has the potential to mitigate autoimmune conditions.

When exploring the practical consequences of this mechanism, the results were conclusive. Experimental autoimmune encephalomyelitis (EAE) and dextran sulfate sodium (DSS)-induced colitis in mice were markedly attenuated when FAM64A was deficient. This correlated with a significant reduction in Th17 cell differentiation and pro-inflammatory cytokine production.

Moreover, the study pushed into the realm of oncogenesis, providing evidence that FAM64A deficiency also suppresses azoxymethane (AOM)/DSS-induced CAC in mice. This implies that FAM64A is not only critical for Th17 cell-mediated inflammation but also plays a direct role in inflammation-associated carcinogenesis.

A Step Forward in Cancer Research and Therapy

The implications of these findings are sweeping and multifaceted. This discovery bridges the gap between understanding cellular processes and developing therapeutic interventions. With FAM64A established as a crucial enhancer of STAT3 activity and subsequent Th17 cell differentiation and inflammation, the potential for targeting this protein to treat related diseases becomes tangible.

Drug development aimed to modulate the activity of STAT3 has long been considered a promising approach to treating cancer. This research adds an extra layer of specificity by identifying FAM64A as a potential novel target. Therapies that specifically inhibit the FAM64A-STAT3 axis could lead to more effective treatment strategies with fewer side effects than treatments targeting STAT3 broadly.

Future Directions and Challenges

The research community eagerly awaits further exploration into this FAM64A-STAT3 interaction. Additional studies are needed to clarify whether these findings in murine models hold true in human pathology. If the FAM64A-related pathway functions similarly in humans, future research could lead to breakthroughs in personalized medicine for treating autoimmunity and cancer, including but not limited to CAC.


The study by Xu and colleagues accentuates how intricate molecular interactions can have broad implications for human health and disease treatment. As researchers continue to unravel these complex pathways, each finding acts as a puzzle piece, gradually forming the larger picture of our biological processes and offering up new ways to manipulate them to treat diseases.

As for medical researchers and healthcare professionals, this study opens a door to targeted therapy options that could revolutionize patient care. For individuals living with inflammatory diseases and cancer, it represents hope for more effective and tailored treatments on the horizon.


1. Xu Zhi-Sheng, et al. FAM64A positively regulates STAT3 activity to promote Th17 differentiation and colitis-associated carcinogenesis. Proc Natl Acad Sci U S A. 2019;116(21):10447-10452. DOI: 10.1073/pnas.1814336116

2. Yu H, et al. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 2009;9:798–809. DOI: 10.1038/nrc2734

3. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med. 2011;365:1612–1623. DOI: 10.1056/NEJMra1100030

4. Yu H, et al. Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer. 2014;14:736–746. DOI: 10.1038/nrc3818

5. Sugimoto K. Role of STAT3 in inflammatory bowel disease. World J Gastroenterol. 2008;14:5110–5114. DOI: 10.3748/wjg.14.5110


1. FAM64A and STAT3 interaction
2. Th17 cell differentiation
3. Colitis-associated cancer treatment
4. Inflammatory diseases therapy
5. STAT3 transcription factor target